中国为早期阿尔茨海默氏症批准LEQEMBI,针对氨基类和原生虫。 China approves LEQEMBI for early Alzheimer’s, targeting amyloid and protofibrils.

针对粉样斑块和有毒原纤维的单克隆抗体LEQEMBI (lecanemab) 在中国已获批,用于每四周内静脉注射一次,用于早期阿尔茨海默病患者的维持剂量,包括轻度认知障碍或轻度痴呆症患者. LEQEMBI (lecanemab), a monoclonal antibody targeting amyloid plaques and toxic protofibrils, has been approved in China for once-every-four-weeks intravenous maintenance dosing in patients with early Alzheimer’s disease, including mild cognitive impairment or mild dementia. Eisai和Biogen开发的治疗基于Clarity Ad研究的第3阶段试验结果,显示认知和功能下降速度减缓。 Developed by Eisai and Biogen, the treatment is based on positive Phase 3 trial results from the Clarity AD study, showing slowed cognitive and functional decline. 已在50个国家获得批准,包括美国,最近还批准了皮下注射,LEQEMBI是唯一一种已获批准的治疗方法,既能向粉样蛋白聚合物,也能向原纤维,从而可能影响疾病的进展. Approved in 50 countries, including the U.S., where a subcutaneous version was recently authorized, LEQEMBI is the only therapy approved to target both amyloid aggregates and protofibrils, potentially influencing disease progression. 估计2024年中国有1700万人受早期阿尔茨海默症影响, 药品供应量旨在应对日益严重的公共卫生挑战。 With an estimated 17 million people in China affected by early Alzheimer’s in 2024, the drug’s availability aims to address a growing public health challenge. Eisai领导中国的全球发展和分销,由Eisai和Biogen共同商业化。 Eisai leads global development and distribution in China, with co-commercialization by Eisai and Biogen.